| Abstract |
Zika virus is a mosquito-borne virus. It is transmitted to humans by infected Aedes spp.mosquitoes. Non-vector-borne transmission routes of Zika virus include blood transfusion-relatedtransmission, sexual transmission, transplacental transmission, and perinatal transmission. Zika virusinfection is asymptomatic in most cases. If symptoms occur, symptoms are generally mild and selflimited. Signs and symptoms, diagnosis and treatment of Zika virus infection in pregnant women aresimilar to non-pregnant women. Zika virus infection in pregnancy is associated with fetal structuralbrain abnormalities and microcephaly. The treatments are symptomatic and supportive. Preventionfrom mosquito bites is the best way to prevent Zika virus infection. Treatment of Zika virus infectionin pregnant women is similar to non-pregnant women. However, obstetricians should be aware ofcongenital Zika virus infection when pregnant women infected with Zika virus especially in the fisttrimester.Materials and Methods: A retrospective cohort study compared first birth teenage deliveries to adult deliveries at Buddhachinaraj Hospital from January 2012 to December 2013.Main Outcome Measurement: Maternal outcomes were anemia, hypertensive disorder, gestational diabetes mellitus, mode of delivery, and postpartum hemorrhage. Neonatal outcomes included preterm delivery, low birth weight, fetal growth restriction and birth asphyxia. Results: The prevalence of teenage pregnancy in this study was 17%. Teenage mothers had less frequent antenatal care. Rates of anemia, preterm delivery and low birth weight were significantly higher in teenage compared to adult pregnancy, whereas the rates of gestational diabetes mellitus and postpartum hemorrhage were lower. Rate of normal vaginal delivery was significantly higher in the teenage group compared to the adult pregnancies. No difference in outcome between groups was demonstrated for hypertensive disorder, infectious disorder, fetal growth restriction and birth asphyxia.Conclusion: Teenage pregnancy had preferable obstetric outcomes for the prevalence of vaginal delivery and postpartum hemorrhage, but had increased neonatal adverse events.Materials and Methods: A retrospective cohort study compared first birth teenage deliveries to adult deliveries at Buddhachinaraj Hospital from January 2012 to December 2013.Main Outcome Measurement: Maternal outcomes were anemia, hypertensive disorder, gestational diabetes mellitus, mode of delivery, and postpartum hemorrhage. Neonatal outcomes included preterm delivery, low birth weight, fetal growth restriction and birth asphyxia. Results: The prevalence of teenage pregnancy in this study was 17%. Teenage mothers had less frequent antenatal care. Rates of anemia, preterm delivery and low birth weight were significantly higher in teenage compared to adult pregnancy, whereas the rates of gestational diabetes mellitus and postpartum hemorrhage were lower. Rate of normal vaginal delivery was significantly higher in the teenage group compared to the adult pregnancies. No difference in outcome between groups was demonstrated for hypertensive disorder, infectious disorder, fetal growth restriction and birth asphyxia.Conclusion: Teenage pregnancy had preferable obstetric outcomes for the prevalence of vaginal delivery and postpartum hemorrhage, but had increased neonatal adverse events.who re-ceived magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital.Study design: Retrospective cross-sectional study.Materials and Methods: A retrospective study from October 1, 2012 to March 31, 2015 was performed to estimate the effect of maternal BMI on serum magnesium level. And 565(2.99 %) pregnant women had severe preeclampsia and eclampsia diagnosed and received magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital. Inclusion criteria was pregnant women delivered at gestational age ? 24 weeks, not expectant management, received magnesium sulfate in regimen loading dose 4 grams, followed by maintenance dose 1 gram/hour intravenously, and monitored serum magnesium level. Serum magnesium level was monitored initially at 3-4 hours after loading dose, and then monitored every 4 hours during magnesium sulfate infusion. The first serum magnesium level after loading dose was used in the study. Association between maternal BMI and subtherapeutic serum magnesium level (magnesium level < 4.8 mg/dL) was evaluated. Results: There are 18,923 women delivered during the study period. Intrapartum serum magnesium levels were monitored in 289 women, 235 women (81.31%) had subtherapeutic magnesium level. Overweight and obese women were associated with higher risk of subtherapeutic serum magnesium level significantly (P value <0.05). Renal insufficiency (creatinine > 1.1 gm/dL) and thrombocytopenia seem to have higher rate of therapeutic magnesium level significantly (P value < 0.05).Conclusion: Most cases of women with severe preeclampsia at Maharat Nakhon Ratchasima Hospital had subtherapeutic serum magnesium level when magnesium sulfate was adminis-tered in regimen loading dose 4 grams, followed by 1 gram per hour intravenously. Over-weight and obesity were high risk factor contributing to subtherapeutic of serum magnesium level.Objectives: To evaluate association between the maternal body mass index (BMI) and sub-therapeutic serum magnesium level in pregnant women with severe preeclampsia who re-ceived magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital.Study design: Retrospective cross-sectional study.Materials and Methods: A retrospective study from October 1, 2012 to March 31, 2015 was performed to estimate the effect of maternal BMI on serum magnesium level. And 565(2.99 %) pregnant women had severe preeclampsia and eclampsia diagnosed and received magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital. Inclusion criteria was pregnant women delivered at gestational age ? 24 weeks, not expectant management, received magnesium sulfate in regimen loading dose 4 grams, followed by maintenance dose 1 gram/hour intravenously, and monitored serum magnesium level. Serum magnesium level was monitored initially at 3-4 hours after loading dose, and then monitored every 4 hours during magnesium sulfate infusion. The first serum magnesium level after loading dose was used in the study. Association between maternal BMI and subtherapeutic serum magnesium level (magnesium level < 4.8 mg/dL) was evaluated. Results: There are 18,923 women delivered during the study period. Intrapartum serum magnesium levels were monitored in 289 women, 235 women (81.31%) had subtherapeutic magnesium level. Overweight and obese women were associated with higher risk of subtherapeutic serum magnesium level significantly (P value <0.05). Renal insufficiency (creatinine > 1.1 gm/dL) and thrombocytopenia seem to have higher rate of therapeutic magnesium level significantly (P value < 0.05).Conclusion: Most cases of women with severe preeclampsia at Maharat Nakhon Ratchasima Hospital had subtherapeutic serum magnesium level when magnesium sulfate was adminis-tered in regimen loading dose 4 grams, followed by 1 gram per hour intravenously. Over-weight and obesity were high risk factor contributing to subtherapeutic of serum magnesium level.Objectives: To evaluate association between the maternal body mass index (BMI) and sub-therapeutic serum magnesium level in pregnant women with severe preeclampsia who re-ceived magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital.Study design: Retrospective cross-sectional study.Materials and Methods: A retrospective study from October 1, 2012 to March 31, 2015 was performed to estimate the effect of maternal BMI on serum magnesium level. And 565(2.99 %) pregnant women had severe preeclampsia and eclampsia diagnosed and received magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital. Inclusion criteria was pregnant women delivered at gestational age ? 24 weeks, not expectant management, received magnesium sulfate in regimen loading dose 4 grams, followed by maintenance dose 1 gram/hour intravenously, and monitored serum magnesium level. Serum magnesium level was monitored initially at 3-4 hours after loading dose, and then monitored every 4 hours during magnesium sulfate infusion. The first serum magnesium level after loading dose was used in the study. Association between maternal BMI and subtherapeutic serum magnesium level (magnesium level < 4.8 mg/dL) was evaluated. Results: There are 18,923 women delivered during the study period. Intrapartum serum magnesium levels were monitored in 289 women, 235 women (81.31%) had subtherapeutic magnesium level. Overweight and obese women were associated with higher risk of subtherapeutic serum magnesium level significantly (P value <0.05). Renal insufficiency (creatinine > 1.1 gm/dL) and thrombocytopenia seem to have higher rate of therapeutic magnesium level significantly (P value < 0.05).Conclusion: Most cases of women with severe preeclampsia at Maharat Nakhon Ratchasima Hospital had subtherapeutic serum magnesium level when magnesium sulfate was adminis-tered in regimen loading dose 4 grams, followed by 1 gram per hour intravenously. Over-weight and obesity were high risk factor contributing to subtherapeutic of serum magnesium level. |
